Slide 1: Neuralstem Inc June 2016 Corporate Presentation
NEURALSTEM INC June 2016 Corporate Presentation
Slide 2: Safe Harbor Statements
NEURALSTEM, INC. Bae sear, saree Safe Harbor statements igation Securities looking statements as dofned in Section Z7A ofthe Socutles Act ot rm Act of 1995: This rward-lo% tee as amen cst, and section 21E of he Securities raeange Act of 1934, as amended. Such ewer Hooking statements are based upon N
Slide 3: Key Highlights
Key Highlights Refocused Business Strategy: — Partner NSI-566 programs May 2016 $9mn Financing NSI-189: Novel Neurogenic Small Molecule targeting MDD — Compelling early clinical data — Intellectual property portfolio, protection expiring from 2016-2034 — Near term milestones: Phase II MDD Data expec
Slide 4: Management
Management President, AstraZeneca Diabetes, US; President, BMS Diabetes, US; Co-| Founder & Partner, SagePath eee) EVP, Takeda P, Commercial Richard Daly, CEO Strategy, TAP Pharmaceuticals + Boards: Cataly: harmaceutical + Education: MBA, | Microbiology, eriversly of Notre Dame * Co-founder, Staff S
Slide 5: NSI-189 Scientific Advisory Board
NSI-189 Scientific Advisory Board World Class Psychiatric, Clinical and Regulatory Experts DO Mauncioleaval Harvard, Meir) cena its Chair, Dept. of Psychiatry Dr. Michael Thase Univ. a Pennsylvania, Chief. Divito of Mood and Anxiety Diso Dr. Mark Frye Mayo Clinic, Chair, Psychiatry and Psychology Un
Slide 6: Pipeline
Pipeline Compound / Indication Preclinical Phase | Phase II Phase III Status* Small Molecule: Lead Asset NSI-189_ US a Results 2H17 Major Depression Disorder esults NSI-189 2) Pipeline Expansion Update 2016 NSI-189 & undisclosed Publications” Multiple POP studies 2016 Cell Therapy (outsourced fundin
Slide 7: MDD Market Opportunity
MDD Market Opportunity ath J 5th -Monotherapy - SSRI/NSRI First Line _TRD1 TRD Il__ 4th line + 33% 17% 10% 40%
Slide 8: NSI-189 Overview
NSI-189 Overview + Unique New Chemical Entity (NCE) + Novel neurogenic lots ¢ Highly st + MDD Market Opportunity rate in MDD’ + Strong IP * Efficac . Competing Phase Ib MDD randomized, double-blind data Large effect size Cognitive eet prot Potential disease Se. durability profile + Excellent safety
Slide 9: Building the Case for MOA
Building the Case for MOA Extensive screening showed novel MOA vs. currently marketed therapies Screening: c 52 neurotransmitter related elas nes channels/enzymes : ABA, Glutamy serotonin anes Cat+, Cl-, K+ rei ee e BDNF release) * 900 other kinases NSI-189 Binding Activities 2 50% at 10uM 14.2 Dopa
Slide 10: Clinical Results from NSI-189 MDD Phase Ib
Clinical Results from NSI-189 MDD Phase Ib NSI- 188 Phase ib double-blind, randomized, placebo-controlled, 1g nd tolerability | Cohort 1 | N=8 (6 drug, 2 placebo) | 40 mg QD | Cohort 2 | N=8 (6 drug, 2 placebo) | 40 mg BID | Cohort 3 | N=8 (6 drug, 2 placebo) | 40 mg TID | Acute treatment: 28 days F
Slide 11: Symptoms of Depression Questionnaire
‘Symptoms of Depression Questionnaire Montgomery and Asberg Depression Rating Scale “0 ‘Study Day seen me reduction in MADRS): 10/18 or 56%; MADRS): 9/18 or 50% Encouraging durable effect ‘Al A Phe 18, Ransomed Dowie Bld Pcao-Contoie ape Gos Excottn Stay Eating te Etat cf NSHHG9 Pape a Neurogenic Co
Slide 12: Clinical Results from NSI-189 MDD Phase Ib
Clinical Results from NSI-189 MDD Phase Ib Day 84 p<0.01 d=1.20 48 40 36 3.0 me Plac: im NS-1 2g] BH NS-189 1x per day —@— NS-189 2x ee pod Oe NS-189 3x 0 ° 20 40 60 80 100 Study Day l Ff d 4 F drug-ft FQ
Slide 13: Biomarker Results from NSI-189 MDD Phase Ib
Biomarker Results from NSI-189 MDD Phase Ib Blood biomarker panel: + Blood panel analysis correlates to MADRS response rate + MDD panel was developed based on SSRIs activity profile + Rapid and persistent efficacy Response | PartialResponder | Responder Rate (<14) +Responders | (250%) i< (250%) By M
Slide 14: Biomarker Results from NSI-189 MDD Phase Ib
Biomarker Results from NSI-189 MDD Phase Ib qEEG Quantitative EEG (qEEG) Hz): Day 28 from Baseline biomarker: NSI-189 Placebo 3 + Increases coherence activity 3 between =n prefrontal cortex and te hippocampus * Two coordinating brain centers 2 utilized for depression and cognition | 3 é Left posteri
Slide 15: NSI-189 MDD Phase Ib: Adverse Events
NSI-189 MDD Phase Ib: Adverse Events Side effect | Pooled placebo | 40mg 4.4. | ame bid. | 401 Poa i ( N(%®) | N(%) | (%) a (n=18) N(%) i) IN (96) ‘Autonomic Dry mouth 0 (0%) 0 (0%) | 2.(33.3%) | 0 (0%) 2 (11.1%) | s Palpitation 0 (0%) 1 (16.7%) | 0 (0%) 0 (0%) 1 (5.6%) | - CNS ipsychiatric Headache
Slide 16: NSI-189 Phase II MDD Trial
NSI-189 Phase II MDD Trial Randomized, Double-Blind, Placebo-Controlled, 2-Dose Study Milestones: ¢ First Patient enrolled May 2016 « Phase 2 Results expected 2H17 Study Objectives * Primary: Montgomery-Asberg Depression Rating Scale (MADRS) * Secondary: SDQ, HAMD17, CGI-S, CPFQ, SFI, Cogscreen Batt
Slide 17: NSI-189 Phase II MDD Trial
NSI-189 Phase II MDD Trial Placebo-reducing, Study Design Innovative Trial Design Experienced MDD trial sites (n=12) ¢ Dual patient screening requirement « Placebo-reducing re-randomization Study Design * Three arm: 40mg BID, 40mg QD, & placebo (n=220 randomized) * Power: >80%, 2-sided ps 0.05; d=0.
Slide 18: Pipeline Expansion
Pipeline Expansion Based onh | 1) ditt Tt f A racy ig our propl y Captures large window of Jevel neurogenesis Multip| ial si faction duri : ple f neurogenesis Anticipated to identify additional ind ( 1. Proliferation 2. Differentiation 3. Maturation/Function } Hippocampal Committed Neurgnal Immature
Slide 19: Key Highlights
Key Highlights Experienced Management Team Recent $9mn Capital Raise of Lead Candidate: NSI-189 novel neurogenic small molecule Protected IP: 2024 (2029 with patent t ‘tensi Chemical Entity Near term miles' - Phase Il MDD oa aa expected 2H17 - Rai. as _ pation: expected 2016 \dditional hi - Piping a
Slide 20: Intellectual Property
Intellectual Property Small Molecule 11 US e 65 World Issued and Pending) elie 89), composition of matter, US mc 560,553) to 2024, Patent Extension ‘0 2029. Assay method f p _ US (8,293,488) and Europe to 2023 — Synthesis method for NSI-189, World-wide to 2030 — Treatment of MDD, World-wide, pending